EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeit

Risk of hypertension after CGRP antagonist treatment in migraine: A systematic review and meta‐analysis

Kunhee Kim iD, Kihun Kim, Su-Yeon Cho, Yujin Kwon, Won Kyu Kim iD, Chaeseong Lim iD, Won Ho Cho iD, Dokyoung Kim iD, Yun Hak Kim iD, Tae-Jin Song iD

Headache: The Journal of Head and Face Pain · 2026

DOI: 10.1111/head.70148 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Headache: The Journal of Head and Face Pain, 2026. Verfasst von Kunhee Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Hypertension, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Ministry of Health & Welfare, Republic of Korea, Ministry of Trade, Industry and Energy, Korea Institute of Science and Technology Intramural Research Grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives/Background This study aimed to systematically summarize and pool the available evidence on the risk of incident hypertension associated with calcitonin gene‐related peptide (CGRP)–targeted therapies. CGRP‐targeted therapies have emerged as effective preventive treatments for migraine; however, concerns have been raised regarding their potential hypertensive effects. Prior studies have been limited by small sample sizes, inconsistent definitions of hypertension, and incomplete trial inclusion.

Methods

We systematically searched MEDLINE, Embase, and ClinicalTrials.gov up to September 25, 2024. We included randomized controlled trials comparing CGRP‐targeted therapies with placebo or another intervention arm in adult patients with migraine. The primary outcome was incident hypertension as defined by each individual study. Two reviewers independently assessed risk of bias using the Cochrane Risk of Bias 2 tool and rated the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach.

Results

Eight publications or trial reports, comprising 19 underlying randomized controlled trials, were included. The pooled relative risk (RR) for hypertension with CGRP‐targeted therapies versus control was 0.91 (95% confidence interval [CI] 0.58–1.43; I ² = 0.0%), indicating no statistically significant increased risk. The certainty of evidence for this outcome was rated as very low. Erenumab showed no significant increase in risk (RR 0.71, 95% CI 0.30–1.70), whereas galcanezumab also showed no statistically significant association (RR 1.14, 95% CI 0.54–2.39).

Conclusion

CGRP‐targeted therapies were not associated with a statistically significant increase in hypertension risk in patients with migraine, particularly among relatively healthy populations enrolled in short‐term randomized controlled trials. However, the certainty of evidence was very low, and possible variation across agents warrants further study. Longer term comparative studies and real‐world observational studies with standardized blood pressure monitoring are needed to confirm these findings and better define hypertension risk in higher risk patient subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersHypertensionCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsHumansRandomized Controlled Trials as TopicAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

calcitonin gene‐related peptidegepanthypertensionmigrainerandomized controlled trial

Substanzen

Calcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
  • Department of Occupational and Environmental Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
  • Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
  • Natural Product Research Center, Korea Institute of Science and Technology (KIST), Gangneung, Republic of Korea.
  • Natural Product Applied Science, KIST School, University of Science and Technology (UST), Gangneung, Republic of Korea.
  • Department of Convergence Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.

ORCID-Profile: Kunhee Kim, Won Kyu Kim, Chaeseong Lim, Won Ho Cho, Dokyoung Kim, Yun Hak Kim, Tae-Jin Song

Förderung

  • Ministry of Health & Welfare, Republic of Korea
  • Ministry of Trade, Industry and Energy
  • Korea Institute of Science and Technology Intramural Research Grants
  • KREONET
  • Korea government (MSIT)
  • Korea Research Environment Open Network
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Kim, K., Kim, K., Cho, S. Y., Kwon, Y., Kim, W. K., Lim, C., Cho, W. H., Kim, D., Kim, Y. H., & Song, T. J. (2026). Risk of hypertension after CGRP antagonist treatment in migraine: A systematic review and meta‐analysis. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70148

Vancouver

Kim K, Kim K, Cho SY, Kwon Y, Kim WK, Lim C, et al. Risk of hypertension after CGRP antagonist treatment in migraine: A systematic review and meta‐analysis. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70148

BibTeX
@article{Kim2026,
  author = {Kim, Kunhee and Kim, Kihun and Cho, Su-Yeon and Kwon, Yujin and Kim, Won Kyu and Lim, Chaeseong and Cho, Won Ho and Kim, Dokyoung and Kim, Yun Hak and Song, Tae-Jin},
  title = {Risk of hypertension after CGRP antagonist treatment in migraine: A systematic review and meta‐analysis},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  doi = {10.1111/head.70148}
}
Kostenlos starten →